175
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study

, , , , , , & show all
Pages 957-966 | Published online: 16 Apr 2019

References

  • KennedySHLamRWMcIntyreRSCanadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatmentsCan J Psychiatry201661954056010.1177/070674371665941727486148
  • TrivediMHRushAJWisniewskiSREvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284010.1176/appi.ajp.163.12.218916390886
  • NierenbergAAPredictors of response to antidepressants general principles and clinical implicationsPsychiatr Clin North Am200326234535210.1016/S0193-953X(02)00105-312778837
  • LamRWOnset, time course and trajectories of improvement with antidepressantsEur Neuropsychopharmacol201222Suppl 3S492S49810.1016/j.euroneuro.2012.07.00522959114
  • StassenHHAngstJHellDScharfetterCSzegediAIs there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patientsJ Clin Psychiatry20076881195120510.4088/JCP.v68n080517854243
  • StassenHHDelini-StulaAAngstJTime course of improvement under antidepressant treatment: a survival-analytical approachEur Neuropsychopharmacol19933212713510.1016/0924-977X(93)90264-M8364348
  • SzegediAJansenWTvan WilligenburgAPvan der MeulenEStassenHHThaseMEEarly improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patientsJ Clin Psychiatry200970334435310.4088/JCP.08m0483919254516
  • SzegediAMullerMJAnghelescuIKlaweCKohnenRBenkertOEarly improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressionJ Clin Psychiatry200364441342010.4088/JCP.v64n041012716243
  • TadicAHelmreichIMerglREarly improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depressionJ Affect Disord20101201–3869310.1016/j.jad.2009.04.01419428118
  • VermeidenMKampermanAMVulinkMEvan den BroekWWBirkenhagerTKEarly improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatientsPsychopharmacology201523281347135610.1007/s00213-014-3765-125338776
  • KudlowPAChaDSMcIntyreRSPredicting treatment response in major depressive disorder: the impact of early symptomatic improvementCan J Psychiatry2012571278278810.1177/07067437120570121123228238
  • EatonNRRodriguez-SeijasCCarragherNKruegerRFTransdiagnostic factors of psychopathology and substance use disorders: a reviewSoc Psychiatry Psychiatr Epidemiol201550217118210.1007/s00127-014-1001-225563838
  • KruegerRFEatonNRTransdiagnostic factors of mental disordersWorld Psychiatry2015141272910.1002/wps.2017525655146
  • PezzoliPAntfolkJSanttilaPPhenotypic factor analysis of psychopathology reveals a new body-related transdiagnostic factorPLoS One2017125e017767410.1371/journal.pone.017767428542328
  • AngstJCuiLSwendsenJMajor depressive disorder with subthreshold bipolarity in the National Comorbidity Survey ReplicationAm J Psychiatry2010167101194120110.1176/appi.ajp.2010.0907101120713498
  • AngstJMerikangasKRCuiLvan MeterAAjdacic-GrossVRosslerWBipolar spectrum in major depressive disordersEur Arch Psychiatry Clin Neurosci2018268874174810.1007/s00406-018-0927-x30032467
  • HaslerGDrevetsWCManjiHKCharneyDSDiscovering endophenotypes for major depressionNeuropsychopharmacology200429101765178110.1038/sj.npp.130050615213704
  • FernandesBSWilliamsLMSteinerJLeboyerMCarvalhoAFBerkMThe new field of ‘precision psychiatry’BMC Med20171518010.1186/s12916-017-0849-x28403846
  • AllenTALamRWMilevREarly change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 reportPsychol Med201811010.1017/S003329171800244.
  • NelsonJCPorteraLLeonACAre there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?Biol Psychiatry200557121535154210.1016/j.biopsych.2004.12.01815953490
  • KatzMMTekellJLBowdenCLOnset and early behavioral effects of pharmacologically different antidepressants and placebo in depressionNeuropsychopharmacology200429356657910.1038/sj.npp.130034114627997
  • YangWCLinCHWangFCLuMJFactors related to the improvement in quality of life for depressed inpatients treated with fluoxetineBMC Psychiatry201717130910.1186/s12888-017-1489-628841824
  • OlfsonMMarcusSCShafferDAntidepressant drug therapy and suicide in severely depressed children and adults: a case-control studyArch Gen Psychiatry200663886587210.1001/archpsyc.63.8.86516894062
  • EysenckHEysenckSManual of the Eysenck personality questionnaireJ Card Fail1975205S67
  • GoodmanWKPriceLHRasmussenSAThe Yale-brown obsessive compulsive scale. I. Development, use, and reliabilityArch Gen Psychiatry198946111006101110.1001/archpsyc.1989.018101100480072684084
  • BernsteinDPSteinJANewcombMDDevelopment and validation of a brief screening version of the childhood trauma questionnaireChild Abuse Negl200327216919010.1016/S0145-2134(02)00541-012615092
  • KroenkeKSpitzerRLWilliamsJBThe PHQ-9: validity of a brief depression severity measureJ Gen Intern Med200116960661310.1046/j.1525-1497.2001.016009606.x11556941
  • SpitzerRLKroenkeKWilliamsJBLoweBA brief measure for assessing generalized anxiety disorder: the GAD-7Arch Intern Med2006166101092109710.1001/archinte.166.17.186316717171
  • BeidelDCBordenJWTurnerSMJacobRGThe social phobia and anxiety inventory: concurrent validity with a clinic sampleBehav Res Ther19892755735762818419
  • MaierWBullerRPhilippMHeuserIThe Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disordersJ Affect Disord198814161682963053
  • KatzMMMeyersALPrakashAGaynorPJHoustonJPEarly symptom change prediction of remission in depression treatmentPsychopharmacol Bull20094219410719204654
  • SakuraiHUchidaHAbeTTrajectories of individual symptoms in remitters versus non-remitters with depressionJ Affect Disord2013151250651310.1016/j.jad.2013.08.00223886402
  • YuYMGaoKRYuHShenYFLiHFEfficacy and safety of agomelatine vs paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, noninferiority, randomized controlled trialJ Clin Psychopharmacol201838322623310.1097/JCP.000000000000087829620692
  • LiGShenYLuoJLiHEfficacy of escitalopram monotherapy in the treatment of major depressive disorder: a pooled analysis of 4 Chinese clinical trialsMedicine (Baltimore)20179639e814210.1097/MD.000000000000814228953649
  • ZisookSLesserIStewartJWEffect of age at onset on the course of major depressive disorderAm J Psychiatry2007164101539154610.1176/ajp.2007.164.5.71217898345
  • BandelowBAndersenHFDolbergOTEscitalopram in the treatment of anxiety symptoms associated with depressionDepress Anxiety2007241536110.1002/(ISSN)1520-639416937393
  • BottelierMASchranteeAVan WingenGRuhéHGDe RuiterMBRenemanLA power analysis for future clinical trials on the potential adverse effects of SSRIs on amygdala reactivityFront Biol201611325625910.1007/s11515-016-1402-6
  • AnsorgeMSZhouMLiraAHenRGingrichJAEarly-life blockade of the 5-HT transporter alters emotional behavior in adult miceScience2004306569787988110.1126/science.306.5698.956a15514160
  • RobertsBWLuoJBrileyDAChowPISuRHillPLA systematic review of personality trait change through interventionPsychol Bull2017143211714110.1037/bul000008828054797
  • AngstJGammaABenazziFAjdacicVEichDRosslerWToward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypo-maniaJ Affect Disord2003731–213314610.1016/S0165-0327(02)00322-112507746
  • SiTWangGYangFEfficacy and safety of escitalopram in treatment of severe depression in Chinese populationMetab Brain Dis201732389190110.1007/s11011-017-9992-528299626
  • NosedaRBorsookDBursteinRNeuropeptides and neurotransmitters that modulate thalamo-cortical pathways relevant to migraine headacheHeadache201757Suppl 29711110.1111/head.13083
  • FavaMMallinckrodtCHDetkeMJWatkinJGWohlreichMMThe effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?J Clin Psychiatry200465452153015119915
  • LinCHYenYCChenMCChenCCRelief of depression and pain improves daily functioning and quality of life in patients with major depressive disorderProg Neuropsychopharmacol Biol Psychiatry201347939810.1016/j.pnpbp.2013.08.00323989033
  • TelangSWaltonCOltenBBlochMHMeta-analysis: second generation antidepressants and headacheJ Affect Disord2018236606810.1016/j.jad.2018.04.04729715610
  • KimDRCzarkowskiKAEppersonCNThe relationship between bipolar disorder, seasonality, and premenstrual symptomsCurr Psychiatry Rep201113650050310.1007/s11920-011-0233-z21918807